SCHEMBL4238709

SCHEMBL4238709

CCCCCNCc1cccc(C(F)(F)F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 1/20 0.64
CYP1A2 P05177 4/20 0.60
CYP2D6 P10635 4/20 0.60
CYP2C19 P33261 4/20 0.60
HTR2A P28223 2/20 0.51
HTR2B P41595 2/20 0.51
SIGMAR1 Q99720 2/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
ADRA2C P18825 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
DRD3 P35462 1/20 0.51
OPRK1 P41145 1/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HTR2C P28335 1/20 0.50
HRH4 Q9H3N8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235847 0.95 SCN8A (0.65) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL4245054 0.89 SCN8A (0.60) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL7981773 0.84 SCN8A (0.59) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL3508827 0.84 SIGMAR1 (0.63) SCN8ACYP1A2CYP2D6CYP2C19SIGMAR1
SCHEMBL10873718 0.83 SCN8A (0.61) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL7249965 0.83 TAAR1 (0.62) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL8032628 0.82 SCN8A (0.57) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL2855040 0.82 HTR2A (0.58) SCN8ACYP1A2CYP2D6CYP2C19HTR2A
SCHEMBL20428086 0.82 CYP1A2 (0.69) CYP1A2CYP2D6CYP2C19SIGMAR1LMNA
SCHEMBL9257479 0.82 CYP1A2 (0.76) CYP1A2CYP2D6CYP2C19SIGMAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAYZME PHARMACEUTICALS LTD. (CA) 2009-05-28 US disclosed
EP-1871357-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE Inflazyme Pharmaceuticals, Ltd. (CA) 2008-01-02 EP disclosed
WO-2006108149-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAZYME PHARMACEUTICALS LTD. (CA) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE CYP2A6, CYP2B6, CYP2D6 SCN8A 1026/4885CYP1A2 8/4885CYP2D6 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.